[1] Abdelwahab Yousef AJ.Male Breast Cancer: Epidemiology and Risk Factors[J]. Semin Oncol, 2017, 44(4): 267-272. [2] Giordano SH, Cohen DS, Buzdar AU, et al.Breast carcinoma in men: a population-based study[J]. Cancer, 2004, 101(1): 51-57. [3] Zongo N, Ouédraogo S, Korsaga-Somé N, et al.Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso)[J]. World J Surg Oncol, 2018, 16(1): 4. [4] Silvestri V, Barrowdale D, Mulligan AM, et al.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2[J]. Breast Cancer Res, 2016, 18(1): 15. [5] 冉然, 吴磊, 王慧, 等. 男性乳腺癌的研究进展[J]. 现代肿瘤医学, 2021, 29(8): 1465-1470. [6] Gucalp A, Traina TA, Eisner JR, et al.Male breast cancer: a disease distinct from female breast cancer[J]. Breast Cancer Res Treat, 2019, 173(1): 37-48. [7] Liu N, Johnson KJ, Ma CX.Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis[J]. Clin Breast Cancer, 2018, 18(5): e997-e1002. [8] Cheang MC, Chia SK, Voduc D, et al.Nielsen, Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer[J]. Natl Cancer Inst, 2009, 101(10): 736-750. [9] Recht A, Comen EA, Fine RE, et al.Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update[J]. Pract Radiat Oncol, 2016, 6(6): e219-e234. [10] Yoney A, Kucuk A, Unsal M.Male breast cancer: a retrospective analysis[J]. Cancer Radiother, 2009, 13: 103-107. [11] 王斌, 连镇, 熊健, 等. 102例男性乳腺癌临床特征及预后分析[J]. 中华普通外科杂志, 2015, 30(1): 23-26. [12] Fentiman I.Male breast cancer: a review[J]. E cancer Med Sci, 2009, 3: 140. [13] Harlan LC, Zujewski JA, Goodman MT, Stevens JL.Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival[J]. Cancer, 2010, 116(15): 3558-3368. [14] Eggemann H, Ignatov A, Smith BJ, et al.Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients[J]. Breast Cancer Res Treat, 2013, 137(2): 465-470. [15] Hassett MJ, Somerfield MR, Baker ER, et al.Management of male breast cancer:ASCO guideline[J]. J Clin Oncol, 2020, 38(16): 1849-1863. [16] Visram H, Kanji F, Dent SF.Endocrine therapy for male breast cancer: rates of toxicity and adherence[J]. Curr Oncol, 2010, 17(5): 17-21. [17] Zagouri F, Sergentanis TN, Azim HA Jr, et al.Aromatase inhibitors in male breast cancer: a pooled analysis[J]. Breast Cancer Res Treat, 2015, 151(1): 141-147. [18] Fentiman IS.Male breast cancer is not congruent with the female disease[J]. Crit Rev Oncol Hemato, 2016, 101: 119-124. [19] Bloom KJ, Govil H, Gattuso P, et al.Status of HER-2 in male and female breast carcinoma[J]. Am J Surg, 2001, 182(4): 389-392. [20] Gucalp A, Traina TA, Eisner JR, et al.Male breast cancer: a disease distinct from female breast cancer[J]. 2019, 173(1): 37-48. [21] Wang F, Shu X, Meszoely I, et al.Overall mortality after diagnosis of breast cancer in men vs women[J]. JAMA Oncol, 2019, 5(1): 1589-1596. |